Latuda

RSS

lurasidone

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Latuda. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Latuda.

For practical information about using Latuda, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 02/09/2019

Authorisation details

Product details
Name
Latuda
Agency product number
EMEA/H/C/002713
Active substance
lurasidone
International non-proprietary name (INN) or common name
lurasidone
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AE05
Publication details
Marketing-authorisation holder
Aziende Chimiche Riunite Angelini Francesco S.p.A.
Revision
17
Date of issue of marketing authorisation valid throughout the European Union
20/03/2014
Contact address
Viale Amelia 70
00181
Roma
Italy

Product information

16/07/2019 Latuda - EMEA/H/C/002713 - N/0027

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Treatment of schizophrenia in adults aged 18 years and over.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
2 ratings